数据中心
龙虎榜
大单追踪
资金流向
业绩预告
新股申购
行情中心
沪深市场
香港市场
美国市场
全球市场
行业风云
全球市场
向上 向下

董事介绍

注:董事持股数取自最新公司公告

姓名 性别 职位 年龄 薪酬 持股数(万股) 截止日期
Michael Sinclair Executive Chairman, Chairman of the Board, Director 74 37.40万美元 未持股 2017-10-13
Roger Crystal Chief Executive Officer, President, Director 41 79.05万美元 未持股 2017-10-13
Geoffrey Wolf Director 64 6.11万美元 未持股 2017-10-13
Ann L. MacDougall Director 63 20.71万美元 未持股 2017-10-13
Gabrielle Silver Director 44 19.74万美元 未持股 2017-10-13
Thomas T. Thomas Director 60 20.94万美元 未持股 2017-10-13

高管介绍

注:高管持股数取自最新公司公告

姓名 性别 职位 年龄 薪酬 持股数(万股) 截止日期
David D. O'Toole Chief Financial Officer, Treasurer, Secretary 58 未披露 未持股 2017-10-13
Michael Sinclair Executive Chairman, Chairman of the Board, Director 74 37.40万美元 未持股 2017-10-13
Roger Crystal Chief Executive Officer, President, Director 41 79.05万美元 未持股 2017-10-13

董事简历

中英对照 |  中文 |  英文
Michael Sinclair

Michael Sinclair自2010年11月29日以来一直担任公司的执行主席和董事。Sinclair博士开发和管理梦百合公司已有40多年。作为一名专门从事精神病学的医生,他于1967年在伦敦Middlesex Hospital开始了他的医疗职业生涯。他于1971年创立Nestor plc并担任其首席执行官时开始向业务转型。他曾担任Nestor公司的首席执行官,导致其股东在8年内的年复合IRR为38。1979年至1982年,他担任INA梦百合Group(后来的CIGNA)及其医院附属公司的国际总裁。他曾担任Lifetime Corporation(他创立的公司)的执行主席,有助于将其KQC子公司从纳什维尔的一个办事处发展成一个营业额10亿美元的企业(1982年至1993年)。1994年,他创立了总部位于美国的大西洋医疗管理有限责任公司(Atlantic Medical Management LLP),管理总部位于纽约的梦百合风险基金Atlantic Medical Capital LP,他在该公司担任董事长直到2001年。Sinclair博士分别自2000年和2016年起担任Advanced Oncotherapy,plc的执行董事长兼首席执行官,并自1993年起担任塔夫茨大学医学院监督员(荣誉退休)董事会成员。


Michael Sinclair has been the Executive Chairman and a director of the Company since November 29 2010. Dr. Sinclair has developed and managed healthcare companies for over forty years. As a physician specializing in psychiatry, he began his medical career at Middlesex Hospital in London in 1967. His transition to business came when he founded and acted as Chief Executive of Nestor PLC in 1971. His tenure as CEO of Nestor resulted in a compound annual IRR of 38 over an 8-year period for its shareholders. He acted as President International of INA Healthcare Group (subsequently CIGNA) and its Hospital Affiliates Inc. subsidiary between 1979 and 1982. As Executive Chairman of Lifetime Corporation, which he founded, he was instrumental in growing its KQC subsidiary from one office in Nashville to a business with a turnover of $1 billion between 1982 and 1993. In 1994 he founded U.S.-based Atlantic Medical Management LLP, which managed the New York based healthcare venture fund, Atlantic Medical Capital LP, where he served as Chairman until 2001. Dr. Sinclair has served as Executive Chairman and Chief Executive Officer of Advanced Oncotherapy, PLC, since 2000 and during 2016 respectively, and also has served on the Board of Overseers (emeritus) of the Tufts University School of Medicine since 1993.
Michael Sinclair自2010年11月29日以来一直担任公司的执行主席和董事。Sinclair博士开发和管理梦百合公司已有40多年。作为一名专门从事精神病学的医生,他于1967年在伦敦Middlesex Hospital开始了他的医疗职业生涯。他于1971年创立Nestor plc并担任其首席执行官时开始向业务转型。他曾担任Nestor公司的首席执行官,导致其股东在8年内的年复合IRR为38。1979年至1982年,他担任INA梦百合Group(后来的CIGNA)及其医院附属公司的国际总裁。他曾担任Lifetime Corporation(他创立的公司)的执行主席,有助于将其KQC子公司从纳什维尔的一个办事处发展成一个营业额10亿美元的企业(1982年至1993年)。1994年,他创立了总部位于美国的大西洋医疗管理有限责任公司(Atlantic Medical Management LLP),管理总部位于纽约的梦百合风险基金Atlantic Medical Capital LP,他在该公司担任董事长直到2001年。Sinclair博士分别自2000年和2016年起担任Advanced Oncotherapy,plc的执行董事长兼首席执行官,并自1993年起担任塔夫茨大学医学院监督员(荣誉退休)董事会成员。
Michael Sinclair has been the Executive Chairman and a director of the Company since November 29 2010. Dr. Sinclair has developed and managed healthcare companies for over forty years. As a physician specializing in psychiatry, he began his medical career at Middlesex Hospital in London in 1967. His transition to business came when he founded and acted as Chief Executive of Nestor PLC in 1971. His tenure as CEO of Nestor resulted in a compound annual IRR of 38 over an 8-year period for its shareholders. He acted as President International of INA Healthcare Group (subsequently CIGNA) and its Hospital Affiliates Inc. subsidiary between 1979 and 1982. As Executive Chairman of Lifetime Corporation, which he founded, he was instrumental in growing its KQC subsidiary from one office in Nashville to a business with a turnover of $1 billion between 1982 and 1993. In 1994 he founded U.S.-based Atlantic Medical Management LLP, which managed the New York based healthcare venture fund, Atlantic Medical Capital LP, where he served as Chairman until 2001. Dr. Sinclair has served as Executive Chairman and Chief Executive Officer of Advanced Oncotherapy, PLC, since 2000 and during 2016 respectively, and also has served on the Board of Overseers (emeritus) of the Tufts University School of Medicine since 1993.
Roger Crystal

Roger Crystal自2009年9月23日起担任公司首席执行官和董事。Crystal博士是开发鼻内纳洛酮治疗阿片类药物过量的先驱。他曾领导公司开发用于阿片类药物过量的鼻用纳洛酮,并获得美国食品和药物管理局(FDA)的批准,也是该产品专利的首席发明人。他曾担任临床医生,并在伦敦帝国理工学院(Imperial College梦百合,London)担任耳鼻喉科医生。他持有the University of Birmingham的医学和生理学学位。他也被授予the Royal College of Surgeons of England的会员。他是伦敦大学学院(University College London)的荣誉研究员,并撰写了多篇同行评议的科学文章。在伦敦商学院(London Business School)获得工商管理硕士学位期间,他曾在高盛(Goldman Sachs)从事并购业务,然后在科尔尼咨询公司(A.T.Kearney)专门从事梦百合战略管理,直到2010年。他曾任职GE梦百合公司的全球业务开发产品收购和许可团队,在那里他负责评估收购、许可和合作交易,直到2014年。最近,他曾担任Imaginab公司(位于洛杉矶的风险投资支持的生物技术公司,开发免疫肿瘤学成像代理)的首席商务官。在此职位上,他领导公司的周转,建立其免疫成像平台的发展战略,并管理其合作伙伴关系,制药公司参与和许可交易。


Roger Crystal has been the Chief Executive Officer and a director of the Company since September 23 2009. Dr. Crystal is a pioneer in the development of intranasal naloxone treatments for opioid overdose. He led the Company’s development of nasal naloxone for opioid overdose, which led to U.S. Food and Drug Administration “FDA” approval, and is the lead inventor on the product’s patents. He has worked as a clinician, and began his career as an ENT surgeon at Imperial College Healthcare, London. He holds degrees in Medicine and Physiology from the University of Birmingham. He was also awarded Membership of The Royal College of Surgeons of England. He was an Honorary Research Fellow at University College London and has authored of a number of peer-reviewed scientific articles. While completing an MBA at London Business School, he worked for Goldman Sachs in mergers and acquisitions and then consulted for A.T. Kearney specializing in healthcare strategy management until 2010. He served on the Global Business Development Product Acquisition and Licensing team at GE Healthcare where he was responsible for evaluating acquisitions, licensing and partnering deals until 2014. Most recently he served as Chief Business Officer for ImaginAb, a Los Angeles based venture capital backed biotechnology company, developing immuno-oncology imaging agents. In this capacity, he led the company’s turnaround, to establish the strategy for the development of its immune-imaging platform and managed its partnerships, pharmaceutical company engagements and licensing deals.
Roger Crystal自2009年9月23日起担任公司首席执行官和董事。Crystal博士是开发鼻内纳洛酮治疗阿片类药物过量的先驱。他曾领导公司开发用于阿片类药物过量的鼻用纳洛酮,并获得美国食品和药物管理局(FDA)的批准,也是该产品专利的首席发明人。他曾担任临床医生,并在伦敦帝国理工学院(Imperial College梦百合,London)担任耳鼻喉科医生。他持有the University of Birmingham的医学和生理学学位。他也被授予the Royal College of Surgeons of England的会员。他是伦敦大学学院(University College London)的荣誉研究员,并撰写了多篇同行评议的科学文章。在伦敦商学院(London Business School)获得工商管理硕士学位期间,他曾在高盛(Goldman Sachs)从事并购业务,然后在科尔尼咨询公司(A.T.Kearney)专门从事梦百合战略管理,直到2010年。他曾任职GE梦百合公司的全球业务开发产品收购和许可团队,在那里他负责评估收购、许可和合作交易,直到2014年。最近,他曾担任Imaginab公司(位于洛杉矶的风险投资支持的生物技术公司,开发免疫肿瘤学成像代理)的首席商务官。在此职位上,他领导公司的周转,建立其免疫成像平台的发展战略,并管理其合作伙伴关系,制药公司参与和许可交易。
Roger Crystal has been the Chief Executive Officer and a director of the Company since September 23 2009. Dr. Crystal is a pioneer in the development of intranasal naloxone treatments for opioid overdose. He led the Company’s development of nasal naloxone for opioid overdose, which led to U.S. Food and Drug Administration “FDA” approval, and is the lead inventor on the product’s patents. He has worked as a clinician, and began his career as an ENT surgeon at Imperial College Healthcare, London. He holds degrees in Medicine and Physiology from the University of Birmingham. He was also awarded Membership of The Royal College of Surgeons of England. He was an Honorary Research Fellow at University College London and has authored of a number of peer-reviewed scientific articles. While completing an MBA at London Business School, he worked for Goldman Sachs in mergers and acquisitions and then consulted for A.T. Kearney specializing in healthcare strategy management until 2010. He served on the Global Business Development Product Acquisition and Licensing team at GE Healthcare where he was responsible for evaluating acquisitions, licensing and partnering deals until 2014. Most recently he served as Chief Business Officer for ImaginAb, a Los Angeles based venture capital backed biotechnology company, developing immuno-oncology imaging agents. In this capacity, he led the company’s turnaround, to establish the strategy for the development of its immune-imaging platform and managed its partnerships, pharmaceutical company engagements and licensing deals.
Geoffrey Wolf

Geoffrey Wolf自2012年12月31日起担任公司董事,自2017年1月29日起担任公司审计委员会、提名和公司治理委员会成员。Wolf先生居住在瑞士。在2008年至2012年期间,Wolf先生管理Vector Assets S.A.,该公司是一家资产管理公司,控制着采矿,石油和天然气,制药,酒店和房地产行业的公司。从2013年到2017年2月,Wolf先生管理GTL Investments Limited(一家资产管理公司,控制采矿,石油和天然气,制药,酒店和房地产行业的公司)。自2017年2月以来,Wolf先生一直是一名自营投资者。他于1976年获得Middlesex University的商业学位。


Geoffrey Wolf has been a director of the Company since December 31 2012 and has been a member of the Company’s Audit Committee and Nominating and Corporate Governance Committee since January 29 2017. Mr. Wolf resides in Switzerland. During 2008 to 2012 Mr. Wolf managed Vector Assets S.A., an asset management company, which controlled companies in the mining, oil and gas, pharmaceuticals, hospitality and real estate industries. From 2013 through February 2017 Mr. Wolf has managed GTL Investments Limited, an asset management company, which controls companies in the mining, oil and gas, pharmaceuticals, hospitality and real estate industries. Since February 2017 Mr. Wolf has been self-employed as an investor. He received a business degree from Middlesex University in 1976.
Geoffrey Wolf自2012年12月31日起担任公司董事,自2017年1月29日起担任公司审计委员会、提名和公司治理委员会成员。Wolf先生居住在瑞士。在2008年至2012年期间,Wolf先生管理Vector Assets S.A.,该公司是一家资产管理公司,控制着采矿,石油和天然气,制药,酒店和房地产行业的公司。从2013年到2017年2月,Wolf先生管理GTL Investments Limited(一家资产管理公司,控制采矿,石油和天然气,制药,酒店和房地产行业的公司)。自2017年2月以来,Wolf先生一直是一名自营投资者。他于1976年获得Middlesex University的商业学位。
Geoffrey Wolf has been a director of the Company since December 31 2012 and has been a member of the Company’s Audit Committee and Nominating and Corporate Governance Committee since January 29 2017. Mr. Wolf resides in Switzerland. During 2008 to 2012 Mr. Wolf managed Vector Assets S.A., an asset management company, which controlled companies in the mining, oil and gas, pharmaceuticals, hospitality and real estate industries. From 2013 through February 2017 Mr. Wolf has managed GTL Investments Limited, an asset management company, which controls companies in the mining, oil and gas, pharmaceuticals, hospitality and real estate industries. Since February 2017 Mr. Wolf has been self-employed as an investor. He received a business degree from Middlesex University in 1976.
Ann L. MacDougall

AnnL.MacDougall自2016年5月5日起担任公司董事,自2017年1月29日起担任公司审计委员会及提名与公司治理委员会成员,自2017年1月29日起担任公司薪酬委员会主席。2014年1月起,她担任Encore.org的总裁,这是一个全国性组织,为在公共或非营利服务领域发展第二职业的个人建立运动。MacDougall从2007年到2013年12月担任Acumen(一家投资基金,专注于为低收入客户提供商品和服务)首席运营官。任职Acumen公司之前,她曾长期任职普华永道会计师事务所(PricewaterhouseCoopers),管理法律事务,包括担任美国总法律顾问,以及位于巴黎的副总法律顾问。MacDougall女士在塔夫茨大学(Tufts University)获得学士学位,在布鲁克林法学院(Brooklyn Law School)获得法学博士学位。


Ann L. MacDougall has been a director of the Company since May 5 2016 has been a member of the Company’s Audit Committee and Nominating and Corporate Governance Committee since January 29 2017 and has been the Chairperson of the Company’s Compensation Committee since January 29 2017. Since January 2014 she has served as President of Encore.org, a national organization building a movement for individuals developing second careers in public or non-profit service. From 2007 to December 2013 Ms. MacDougall was Chief Operating Officer of Acumen, an investment fund focused on goods and services for low-income customers. Prior to Acumen, she had a long career managing legal matters at PriceWaterhouseCoopers, including as General Counsel in the U.S. and Deputy General Counsel based in Paris. Ms. MacDougall earned her B.A. at Tufts University and her J.D. at Brooklyn Law School.
AnnL.MacDougall自2016年5月5日起担任公司董事,自2017年1月29日起担任公司审计委员会及提名与公司治理委员会成员,自2017年1月29日起担任公司薪酬委员会主席。2014年1月起,她担任Encore.org的总裁,这是一个全国性组织,为在公共或非营利服务领域发展第二职业的个人建立运动。MacDougall从2007年到2013年12月担任Acumen(一家投资基金,专注于为低收入客户提供商品和服务)首席运营官。任职Acumen公司之前,她曾长期任职普华永道会计师事务所(PricewaterhouseCoopers),管理法律事务,包括担任美国总法律顾问,以及位于巴黎的副总法律顾问。MacDougall女士在塔夫茨大学(Tufts University)获得学士学位,在布鲁克林法学院(Brooklyn Law School)获得法学博士学位。
Ann L. MacDougall has been a director of the Company since May 5 2016 has been a member of the Company’s Audit Committee and Nominating and Corporate Governance Committee since January 29 2017 and has been the Chairperson of the Company’s Compensation Committee since January 29 2017. Since January 2014 she has served as President of Encore.org, a national organization building a movement for individuals developing second careers in public or non-profit service. From 2007 to December 2013 Ms. MacDougall was Chief Operating Officer of Acumen, an investment fund focused on goods and services for low-income customers. Prior to Acumen, she had a long career managing legal matters at PriceWaterhouseCoopers, including as General Counsel in the U.S. and Deputy General Counsel based in Paris. Ms. MacDougall earned her B.A. at Tufts University and her J.D. at Brooklyn Law School.
Gabrielle Silver

Gabrielle Silver自2016年5月5日起担任公司董事,自2017年1月29日起担任公司提名和公司治理委员会主席,自2017年5月26日起担任公司薪酬委员会成员。2015年10月以来,她一直担任Brunswick Group(咨询公司,专注于关键问题和企业关系)的合伙人,在那里她共同领导该公司的全球制药和梦百合产品。Silver自2015年9月起担任英国伦敦Royal National Orthopaedic Hospital副非执行董事。从2013年10月到2015年10月,她曾担任GE梦百合的手术室解决方案业务(GE梦百合的一个新部门)的高管。从2010年9月到2013年10月,她曾担任GE公司的神经科学/通用医学战略营销全球主管。在这个职位上,她开发了诊断和成像投资组合中以疾病为重点的增长策略。职业生涯早期,她曾担任Eisai Ltd.(英国)的CNS特许经营董事,负责英国关键品牌的增长和盈利能力,包括Aricept®;和Zonegran®;。任职Eisai公司之前,她曾担任Bristol-Myers Squibb UK公司的神经科学治疗区域董事。Silver博士在布里斯托尔大学(University of Bristol)获得理学学士学位,并在伦敦大学(University of London)获得医学学士学位和外科学士学位。她也是英国the Faculty of Pharmaceutical Medicine的研究员。


Gabrielle Silver has been a director of the Company since May 5 2016 has been the Chairperson of the Company’s Nominating and Corporate Governance Committee since January 29 2017 and has been a member of the Company’s Compensation Committee since May 26 2017. Since October 2015 she has served as a partner at Brunswick Group, an advisory firm specializing in critical issues and corporate relations, where she is co-leading the firm’s global pharmaceutical and healthcare offering. Since September 2015 Dr. Silver has served as an associate non-executive director of The Royal National Orthopaedic Hospital in London, England. From October 2013 to October 2015 she was an executive at GE Healthcare’s Operating Room Solutions business, a new division at GE Healthcare. From September 2010 to October 2013 she was Global Head of Neuroscience/General Medicine Strategic Marketing at GE. In this role, she developed the disease-focused growth strategy across the diagnostics and imaging portfolio. Earlier in her career, Dr. Silver was the director of the CNS Franchise of Eisai Ltd., UK for which she was responsible for growth and profitability of key brands in the UK including Aricept® and Zonegran®. Prior to her tenure at Eisai, she was Therapeutic Area Director of Neuroscience at Bristol-Myers Squibb UK. Dr. Silver received her Bachelor of Science from the University of Bristol and her Bachelor of Medicine and Bachelor of Surgery from the University of London. She is also a Fellow of the Faculty of Pharmaceutical Medicine in the UK.
Gabrielle Silver自2016年5月5日起担任公司董事,自2017年1月29日起担任公司提名和公司治理委员会主席,自2017年5月26日起担任公司薪酬委员会成员。2015年10月以来,她一直担任Brunswick Group(咨询公司,专注于关键问题和企业关系)的合伙人,在那里她共同领导该公司的全球制药和梦百合产品。Silver自2015年9月起担任英国伦敦Royal National Orthopaedic Hospital副非执行董事。从2013年10月到2015年10月,她曾担任GE梦百合的手术室解决方案业务(GE梦百合的一个新部门)的高管。从2010年9月到2013年10月,她曾担任GE公司的神经科学/通用医学战略营销全球主管。在这个职位上,她开发了诊断和成像投资组合中以疾病为重点的增长策略。职业生涯早期,她曾担任Eisai Ltd.(英国)的CNS特许经营董事,负责英国关键品牌的增长和盈利能力,包括Aricept®;和Zonegran®;。任职Eisai公司之前,她曾担任Bristol-Myers Squibb UK公司的神经科学治疗区域董事。Silver博士在布里斯托尔大学(University of Bristol)获得理学学士学位,并在伦敦大学(University of London)获得医学学士学位和外科学士学位。她也是英国the Faculty of Pharmaceutical Medicine的研究员。
Gabrielle Silver has been a director of the Company since May 5 2016 has been the Chairperson of the Company’s Nominating and Corporate Governance Committee since January 29 2017 and has been a member of the Company’s Compensation Committee since May 26 2017. Since October 2015 she has served as a partner at Brunswick Group, an advisory firm specializing in critical issues and corporate relations, where she is co-leading the firm’s global pharmaceutical and healthcare offering. Since September 2015 Dr. Silver has served as an associate non-executive director of The Royal National Orthopaedic Hospital in London, England. From October 2013 to October 2015 she was an executive at GE Healthcare’s Operating Room Solutions business, a new division at GE Healthcare. From September 2010 to October 2013 she was Global Head of Neuroscience/General Medicine Strategic Marketing at GE. In this role, she developed the disease-focused growth strategy across the diagnostics and imaging portfolio. Earlier in her career, Dr. Silver was the director of the CNS Franchise of Eisai Ltd., UK for which she was responsible for growth and profitability of key brands in the UK including Aricept® and Zonegran®. Prior to her tenure at Eisai, she was Therapeutic Area Director of Neuroscience at Bristol-Myers Squibb UK. Dr. Silver received her Bachelor of Science from the University of Bristol and her Bachelor of Medicine and Bachelor of Surgery from the University of London. She is also a Fellow of the Faculty of Pharmaceutical Medicine in the UK.
Thomas T. Thomas

ThomasT.Thomas自2016年11月4日起担任公司董事,自2017年1月29日起担任公司审计委员会,薪酬委员会主席,自2017年1月29日起担任公司提名和公司治理委员会成员。Thomas先生自2011年以来一直从事个体经营,为各种技术,饮料以及食品和生物技术公司提供金融,投资和风险管理咨询服务。2009年,托马斯先生加入了斯图普斯基基金会(Stupski Foundation&8220;Stupski&8221;),这是一家专注于改革公共教育体系的基金会,并将其作为首席财务官。Thomas先生于2010年被提升为首席运营官,并担任Stupski&8217;的临时首席执行官,然后于2010年末离开Stupski以寻求咨询机会。在加入Stupski之前,Thomas先生在生物制药公司Genentech,Inc.(“;Genentech”;)工作了12年,担任过各种财务职务,最终从2001年到2006年担任该公司的公司财务主管。他在Genentech的执行职责包括财务运营、现金和投资管理、企业融资、全球采购、企业风险管理、业务连续性和房地产金融和行政。从1990年到1994年,他曾担任Del Monte Foods公司的财务战略经理,并于1988年在GE Capital Corporation(&8220;GE&8221;)开始他的职业生涯,担任GE&8217;s Corporate Finance Group(专注于杠杆收购和破产融资)的分析师。Thomas先生目前任职于加州癌症预防研究所(Cancer Prevention Institute of California)的董事会,此前曾任职于旧金山安全分析师和Hospitality House的董事会。他也是the Ivy Exec Mentorship Network的导师。Thomas先生是一名特许金融分析师,并在辛辛那提大学(University of Cincinnati)获得工商管理硕士学位,在那里他是研究生,并在辛辛那提大学音乐学院(University of Cincinnati’;s College-Conservatory of Music)获得音乐学士学位。


Thomas T. Thomas has been a director of the Company since November 4 2016 has been the Chairperson of the Company’s Audit Committee, Compensation Committee since January 29 2017 and has been a member of the Company’s Nominating and Corporate Governance Committee since January 29 2017. Since 2011 Mr. Thomas has been self-employed providing financial, investment and risk management consulting services to a variety of technology, beverage and food and biotechnology companies. In 2009 Mr. Thomas joined the Stupski Foundation “Stupski”, a foundation focused on transforming the public education system, as its chief financial officer. In 2010 Mr. Thomas was promoted to chief operating officer and served as Stupski’s interim chief executive officer before leaving Stupski in late 2010 to pursue consulting opportunities. Prior to joining Stupski, Mr. Thomas spent 12 years at Genentech, Inc. (“Genentech”), a biopharmaceutical company, in various financial roles, ultimately serving as the company’s corporate treasurer from 2001 to 2006. His executive responsibilities at Genentech included treasury operations, cash and investment management, corporate finance, global procurement, enterprise risk management, business continuity and real estate finance and administration. From 1990 to 1994 Mr. Thomas was a manager of financial strategy with Del Monte Foods and he began his career in 1988 at GE Capital Corporation (“GE”) as an analyst in GE’s corporate finance group, which focused on leveraged buyouts and bankruptcy financing. Mr. Thomas currently serves on the board of trustees of the Cancer Prevention Institute of California and has previously served on the boards of the San Francisco Security Analysts and Hospitality House. He is also a mentor in the Ivy Exec Mentorship Network. Mr. Thomas is a Chartered Financial Analyst and received his Master of Business Administration from the University of Cincinnati, where he was a Graduate Fellow, and a Bachelor of Music from the University of Cincinnati’s College-Conservatory of Music.
ThomasT.Thomas自2016年11月4日起担任公司董事,自2017年1月29日起担任公司审计委员会,薪酬委员会主席,自2017年1月29日起担任公司提名和公司治理委员会成员。Thomas先生自2011年以来一直从事个体经营,为各种技术,饮料以及食品和生物技术公司提供金融,投资和风险管理咨询服务。2009年,托马斯先生加入了斯图普斯基基金会(Stupski Foundation&8220;Stupski&8221;),这是一家专注于改革公共教育体系的基金会,并将其作为首席财务官。Thomas先生于2010年被提升为首席运营官,并担任Stupski&8217;的临时首席执行官,然后于2010年末离开Stupski以寻求咨询机会。在加入Stupski之前,Thomas先生在生物制药公司Genentech,Inc.(“;Genentech”;)工作了12年,担任过各种财务职务,最终从2001年到2006年担任该公司的公司财务主管。他在Genentech的执行职责包括财务运营、现金和投资管理、企业融资、全球采购、企业风险管理、业务连续性和房地产金融和行政。从1990年到1994年,他曾担任Del Monte Foods公司的财务战略经理,并于1988年在GE Capital Corporation(&8220;GE&8221;)开始他的职业生涯,担任GE&8217;s Corporate Finance Group(专注于杠杆收购和破产融资)的分析师。Thomas先生目前任职于加州癌症预防研究所(Cancer Prevention Institute of California)的董事会,此前曾任职于旧金山安全分析师和Hospitality House的董事会。他也是the Ivy Exec Mentorship Network的导师。Thomas先生是一名特许金融分析师,并在辛辛那提大学(University of Cincinnati)获得工商管理硕士学位,在那里他是研究生,并在辛辛那提大学音乐学院(University of Cincinnati’;s College-Conservatory of Music)获得音乐学士学位。
Thomas T. Thomas has been a director of the Company since November 4 2016 has been the Chairperson of the Company’s Audit Committee, Compensation Committee since January 29 2017 and has been a member of the Company’s Nominating and Corporate Governance Committee since January 29 2017. Since 2011 Mr. Thomas has been self-employed providing financial, investment and risk management consulting services to a variety of technology, beverage and food and biotechnology companies. In 2009 Mr. Thomas joined the Stupski Foundation “Stupski”, a foundation focused on transforming the public education system, as its chief financial officer. In 2010 Mr. Thomas was promoted to chief operating officer and served as Stupski’s interim chief executive officer before leaving Stupski in late 2010 to pursue consulting opportunities. Prior to joining Stupski, Mr. Thomas spent 12 years at Genentech, Inc. (“Genentech”), a biopharmaceutical company, in various financial roles, ultimately serving as the company’s corporate treasurer from 2001 to 2006. His executive responsibilities at Genentech included treasury operations, cash and investment management, corporate finance, global procurement, enterprise risk management, business continuity and real estate finance and administration. From 1990 to 1994 Mr. Thomas was a manager of financial strategy with Del Monte Foods and he began his career in 1988 at GE Capital Corporation (“GE”) as an analyst in GE’s corporate finance group, which focused on leveraged buyouts and bankruptcy financing. Mr. Thomas currently serves on the board of trustees of the Cancer Prevention Institute of California and has previously served on the boards of the San Francisco Security Analysts and Hospitality House. He is also a mentor in the Ivy Exec Mentorship Network. Mr. Thomas is a Chartered Financial Analyst and received his Master of Business Administration from the University of Cincinnati, where he was a Graduate Fellow, and a Bachelor of Music from the University of Cincinnati’s College-Conservatory of Music.

高管简历

中英对照 |  中文 |  英文
David D. O'Toole

David D. O'Toole于2014年7月被任命为Soleno Therapeutics, Inc.首席财务官。他在会计和金融领域拥有30多年的经验,过去14年一直专注于医疗器械、工具和诊断行业。2012年9月至2014年6月,O'Toole先生担任Codexis, Inc.的高级Vice President兼首席财务官,Codexis, Inc.是一家专注于开发生物催化剂的上市公司。2010年5月至2012年8月,O'Toole先生担任Response Genetics, Inc.Vice President兼首席财务官,并于2008年5月至2010年8月担任阿布拉西斯生物执行Vice President兼首席财务官,Inc.从1992年到2008年,O'Toole先生在Deloitte & Touche LLP工作,在那里他担任了12年的合伙人。1984年至1992年,他在Arthur Anderson & Co.担任国际税务经理。O'Toole先生在亚利桑那大学获得会计学理学学士学位,是一名注册会计师。


David D. O'Toole has been the Chief Financial Officer of the Company since September 12 2017 the Treasurer and Secretary of the Company since October 5 2017 and a director of Opiant UK since September 12 2017. From 2014 to 2017 he served as the Chief Financial Officer at Soleno Therapeutics, Inc. "Soleno", a company focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. Mr. O'Toole managed Soleno's initial public offering in 2014 and raised over $40 million for the company in a number of financing transactions. During the last nine years as the Chief Financial Officer of four life sciences companies, Mr. O'Toole has led numerous M&A and financing transactions. He has worked in SEC reporting, managing and building finance, treasury and accounting departments, Sarbanes-Oxley Act of 2002 compliance and managing investor relations and commercial operations. Prior to Soleno, Mr. O'Toole served as the Chief Financial Officer at Codexis, Inc. from 2012 to 2014 and Response Genetics, Inc. from 2010 to 2012. Prior to that, from 2008 to 2009 Mr. O'Toole served as Chief Financial Officer at Abraxis BioScience, Inc., which was acquired by Celgene for $2.9 billion. Mr. O'Toole spent 24 years in public accounting, including 16 years with the accounting firm of Deloitte & Touche LLP, including 12 years as a partner, and began his career with 8 years at the accounting firm of Arthur Andersen. Mr. O'Toole holds a Bachelor of Science degree in accounting from the University of Arizona and is a Certified Public Accountant. As the Company's Chief Financial Officer, Mr. O'Toole is responsible for all aspects of financial management for the Company.
David D. O'Toole于2014年7月被任命为Soleno Therapeutics, Inc.首席财务官。他在会计和金融领域拥有30多年的经验,过去14年一直专注于医疗器械、工具和诊断行业。2012年9月至2014年6月,O'Toole先生担任Codexis, Inc.的高级Vice President兼首席财务官,Codexis, Inc.是一家专注于开发生物催化剂的上市公司。2010年5月至2012年8月,O'Toole先生担任Response Genetics, Inc.Vice President兼首席财务官,并于2008年5月至2010年8月担任阿布拉西斯生物执行Vice President兼首席财务官,Inc.从1992年到2008年,O'Toole先生在Deloitte & Touche LLP工作,在那里他担任了12年的合伙人。1984年至1992年,他在Arthur Anderson & Co.担任国际税务经理。O'Toole先生在亚利桑那大学获得会计学理学学士学位,是一名注册会计师。
David D. O'Toole has been the Chief Financial Officer of the Company since September 12 2017 the Treasurer and Secretary of the Company since October 5 2017 and a director of Opiant UK since September 12 2017. From 2014 to 2017 he served as the Chief Financial Officer at Soleno Therapeutics, Inc. "Soleno", a company focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. Mr. O'Toole managed Soleno's initial public offering in 2014 and raised over $40 million for the company in a number of financing transactions. During the last nine years as the Chief Financial Officer of four life sciences companies, Mr. O'Toole has led numerous M&A and financing transactions. He has worked in SEC reporting, managing and building finance, treasury and accounting departments, Sarbanes-Oxley Act of 2002 compliance and managing investor relations and commercial operations. Prior to Soleno, Mr. O'Toole served as the Chief Financial Officer at Codexis, Inc. from 2012 to 2014 and Response Genetics, Inc. from 2010 to 2012. Prior to that, from 2008 to 2009 Mr. O'Toole served as Chief Financial Officer at Abraxis BioScience, Inc., which was acquired by Celgene for $2.9 billion. Mr. O'Toole spent 24 years in public accounting, including 16 years with the accounting firm of Deloitte & Touche LLP, including 12 years as a partner, and began his career with 8 years at the accounting firm of Arthur Andersen. Mr. O'Toole holds a Bachelor of Science degree in accounting from the University of Arizona and is a Certified Public Accountant. As the Company's Chief Financial Officer, Mr. O'Toole is responsible for all aspects of financial management for the Company.
Michael Sinclair

Michael Sinclair自2010年11月29日以来一直担任公司的执行主席和董事。Sinclair博士开发和管理梦百合公司已有40多年。作为一名专门从事精神病学的医生,他于1967年在伦敦Middlesex Hospital开始了他的医疗职业生涯。他于1971年创立Nestor plc并担任其首席执行官时开始向业务转型。他曾担任Nestor公司的首席执行官,导致其股东在8年内的年复合IRR为38。1979年至1982年,他担任INA梦百合Group(后来的CIGNA)及其医院附属公司的国际总裁。他曾担任Lifetime Corporation(他创立的公司)的执行主席,有助于将其KQC子公司从纳什维尔的一个办事处发展成一个营业额10亿美元的企业(1982年至1993年)。1994年,他创立了总部位于美国的大西洋医疗管理有限责任公司(Atlantic Medical Management LLP),管理总部位于纽约的梦百合风险基金Atlantic Medical Capital LP,他在该公司担任董事长直到2001年。Sinclair博士分别自2000年和2016年起担任Advanced Oncotherapy,plc的执行董事长兼首席执行官,并自1993年起担任塔夫茨大学医学院监督员(荣誉退休)董事会成员。


Michael Sinclair has been the Executive Chairman and a director of the Company since November 29 2010. Dr. Sinclair has developed and managed healthcare companies for over forty years. As a physician specializing in psychiatry, he began his medical career at Middlesex Hospital in London in 1967. His transition to business came when he founded and acted as Chief Executive of Nestor PLC in 1971. His tenure as CEO of Nestor resulted in a compound annual IRR of 38 over an 8-year period for its shareholders. He acted as President International of INA Healthcare Group (subsequently CIGNA) and its Hospital Affiliates Inc. subsidiary between 1979 and 1982. As Executive Chairman of Lifetime Corporation, which he founded, he was instrumental in growing its KQC subsidiary from one office in Nashville to a business with a turnover of $1 billion between 1982 and 1993. In 1994 he founded U.S.-based Atlantic Medical Management LLP, which managed the New York based healthcare venture fund, Atlantic Medical Capital LP, where he served as Chairman until 2001. Dr. Sinclair has served as Executive Chairman and Chief Executive Officer of Advanced Oncotherapy, PLC, since 2000 and during 2016 respectively, and also has served on the Board of Overseers (emeritus) of the Tufts University School of Medicine since 1993.
Michael Sinclair自2010年11月29日以来一直担任公司的执行主席和董事。Sinclair博士开发和管理梦百合公司已有40多年。作为一名专门从事精神病学的医生,他于1967年在伦敦Middlesex Hospital开始了他的医疗职业生涯。他于1971年创立Nestor plc并担任其首席执行官时开始向业务转型。他曾担任Nestor公司的首席执行官,导致其股东在8年内的年复合IRR为38。1979年至1982年,他担任INA梦百合Group(后来的CIGNA)及其医院附属公司的国际总裁。他曾担任Lifetime Corporation(他创立的公司)的执行主席,有助于将其KQC子公司从纳什维尔的一个办事处发展成一个营业额10亿美元的企业(1982年至1993年)。1994年,他创立了总部位于美国的大西洋医疗管理有限责任公司(Atlantic Medical Management LLP),管理总部位于纽约的梦百合风险基金Atlantic Medical Capital LP,他在该公司担任董事长直到2001年。Sinclair博士分别自2000年和2016年起担任Advanced Oncotherapy,plc的执行董事长兼首席执行官,并自1993年起担任塔夫茨大学医学院监督员(荣誉退休)董事会成员。
Michael Sinclair has been the Executive Chairman and a director of the Company since November 29 2010. Dr. Sinclair has developed and managed healthcare companies for over forty years. As a physician specializing in psychiatry, he began his medical career at Middlesex Hospital in London in 1967. His transition to business came when he founded and acted as Chief Executive of Nestor PLC in 1971. His tenure as CEO of Nestor resulted in a compound annual IRR of 38 over an 8-year period for its shareholders. He acted as President International of INA Healthcare Group (subsequently CIGNA) and its Hospital Affiliates Inc. subsidiary between 1979 and 1982. As Executive Chairman of Lifetime Corporation, which he founded, he was instrumental in growing its KQC subsidiary from one office in Nashville to a business with a turnover of $1 billion between 1982 and 1993. In 1994 he founded U.S.-based Atlantic Medical Management LLP, which managed the New York based healthcare venture fund, Atlantic Medical Capital LP, where he served as Chairman until 2001. Dr. Sinclair has served as Executive Chairman and Chief Executive Officer of Advanced Oncotherapy, PLC, since 2000 and during 2016 respectively, and also has served on the Board of Overseers (emeritus) of the Tufts University School of Medicine since 1993.
Roger Crystal

Roger Crystal自2009年9月23日起担任公司首席执行官和董事。Crystal博士是开发鼻内纳洛酮治疗阿片类药物过量的先驱。他曾领导公司开发用于阿片类药物过量的鼻用纳洛酮,并获得美国食品和药物管理局(FDA)的批准,也是该产品专利的首席发明人。他曾担任临床医生,并在伦敦帝国理工学院(Imperial College梦百合,London)担任耳鼻喉科医生。他持有the University of Birmingham的医学和生理学学位。他也被授予the Royal College of Surgeons of England的会员。他是伦敦大学学院(University College London)的荣誉研究员,并撰写了多篇同行评议的科学文章。在伦敦商学院(London Business School)获得工商管理硕士学位期间,他曾在高盛(Goldman Sachs)从事并购业务,然后在科尔尼咨询公司(A.T.Kearney)专门从事梦百合战略管理,直到2010年。他曾任职GE梦百合公司的全球业务开发产品收购和许可团队,在那里他负责评估收购、许可和合作交易,直到2014年。最近,他曾担任Imaginab公司(位于洛杉矶的风险投资支持的生物技术公司,开发免疫肿瘤学成像代理)的首席商务官。在此职位上,他领导公司的周转,建立其免疫成像平台的发展战略,并管理其合作伙伴关系,制药公司参与和许可交易。


Roger Crystal has been the Chief Executive Officer and a director of the Company since September 23 2009. Dr. Crystal is a pioneer in the development of intranasal naloxone treatments for opioid overdose. He led the Company’s development of nasal naloxone for opioid overdose, which led to U.S. Food and Drug Administration “FDA” approval, and is the lead inventor on the product’s patents. He has worked as a clinician, and began his career as an ENT surgeon at Imperial College Healthcare, London. He holds degrees in Medicine and Physiology from the University of Birmingham. He was also awarded Membership of The Royal College of Surgeons of England. He was an Honorary Research Fellow at University College London and has authored of a number of peer-reviewed scientific articles. While completing an MBA at London Business School, he worked for Goldman Sachs in mergers and acquisitions and then consulted for A.T. Kearney specializing in healthcare strategy management until 2010. He served on the Global Business Development Product Acquisition and Licensing team at GE Healthcare where he was responsible for evaluating acquisitions, licensing and partnering deals until 2014. Most recently he served as Chief Business Officer for ImaginAb, a Los Angeles based venture capital backed biotechnology company, developing immuno-oncology imaging agents. In this capacity, he led the company’s turnaround, to establish the strategy for the development of its immune-imaging platform and managed its partnerships, pharmaceutical company engagements and licensing deals.
Roger Crystal自2009年9月23日起担任公司首席执行官和董事。Crystal博士是开发鼻内纳洛酮治疗阿片类药物过量的先驱。他曾领导公司开发用于阿片类药物过量的鼻用纳洛酮,并获得美国食品和药物管理局(FDA)的批准,也是该产品专利的首席发明人。他曾担任临床医生,并在伦敦帝国理工学院(Imperial College梦百合,London)担任耳鼻喉科医生。他持有the University of Birmingham的医学和生理学学位。他也被授予the Royal College of Surgeons of England的会员。他是伦敦大学学院(University College London)的荣誉研究员,并撰写了多篇同行评议的科学文章。在伦敦商学院(London Business School)获得工商管理硕士学位期间,他曾在高盛(Goldman Sachs)从事并购业务,然后在科尔尼咨询公司(A.T.Kearney)专门从事梦百合战略管理,直到2010年。他曾任职GE梦百合公司的全球业务开发产品收购和许可团队,在那里他负责评估收购、许可和合作交易,直到2014年。最近,他曾担任Imaginab公司(位于洛杉矶的风险投资支持的生物技术公司,开发免疫肿瘤学成像代理)的首席商务官。在此职位上,他领导公司的周转,建立其免疫成像平台的发展战略,并管理其合作伙伴关系,制药公司参与和许可交易。
Roger Crystal has been the Chief Executive Officer and a director of the Company since September 23 2009. Dr. Crystal is a pioneer in the development of intranasal naloxone treatments for opioid overdose. He led the Company’s development of nasal naloxone for opioid overdose, which led to U.S. Food and Drug Administration “FDA” approval, and is the lead inventor on the product’s patents. He has worked as a clinician, and began his career as an ENT surgeon at Imperial College Healthcare, London. He holds degrees in Medicine and Physiology from the University of Birmingham. He was also awarded Membership of The Royal College of Surgeons of England. He was an Honorary Research Fellow at University College London and has authored of a number of peer-reviewed scientific articles. While completing an MBA at London Business School, he worked for Goldman Sachs in mergers and acquisitions and then consulted for A.T. Kearney specializing in healthcare strategy management until 2010. He served on the Global Business Development Product Acquisition and Licensing team at GE Healthcare where he was responsible for evaluating acquisitions, licensing and partnering deals until 2014. Most recently he served as Chief Business Officer for ImaginAb, a Los Angeles based venture capital backed biotechnology company, developing immuno-oncology imaging agents. In this capacity, he led the company’s turnaround, to establish the strategy for the development of its immune-imaging platform and managed its partnerships, pharmaceutical company engagements and licensing deals.